Survey Study on Barrett's Esophagus Screening
(SCREEN-BE Trial)

Recruiting in Palo Alto (17 mi)

+6 other locations

Overseen bySachin Wani, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Colorado, Denver

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this study is to optimize Barrett's Esophagus (BE) screening to reduce the incidence, morbidity, and mortality of Esophageal Adenocarcinoma (EAC).

Research Team

Sachin Wani, MD

Principal Investigator

University of Colorado, Denver

Eligibility Criteria

Inclusion Criteria

Patient Eligibility Criteria

Patients identified by ICD-10 codes for GERD (K21.0 and K21.9)

Have had at least one outpatient clinic visit at a participating site

Treatment Details

Interventions

Gastroenterologist Survey (Behavioral Intervention)
Patient Survey (Behavioral Intervention)
Primary Care Provider Survey (Behavioral Intervention)

Participant Groups

3Treatment groups

Experimental Treatment

Group I: Primary Care ProvidersExperimental Treatment1 Intervention

400 eligible primary care providers (PCPs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible PCPs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for providers to complete a paper survey at PCP clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.

Group II: PatientsExperimental Treatment1 Intervention

500 eligible patients will be recruited across the 7 participating sites to complete a survey. The survey will be distributed to eligible patients at the time of a clinic appointment, via telephone, or via a REDCap internet survey that will allow for 2 additional electronic phone call reminders and 1 email reminder.

Group III: GastroenterologistsExperimental Treatment1 Intervention

100 eligible gastroenterologists (GIs) will be recruited across the 7 participating sites to complete an anonymous survey. The survey will be distributed to eligible GIs by the study site research coordinator via anonymous REDCap internet survey with 2 additional automated electronic reminders. There will also be opportunities for GIs to complete a paper survey at provider clinic meetings which will be collected by only the site research coordinator to maintain response anonymity.